-
Overview
Date & Location
8/24/2022 – 8/24/2023, 12:00 AM CST Online
Overview
This podcast discusses updates in outpatient strategies for COVID-19 patients. Information on what outpatients with COVID-19 should be receiving is explained. Approved therapies for COVID-19 and who benefit most from these therapies as well as agent that should not be used or discussed in this podcast. Future strategies and agents on the horizon for COVID-19 are also discussed.
Target Audience
This educational activity is designed to meet the educational goals of physicians and other healthcare professionals specializing in infectious diseases, family and community medicine, internal medicine, emergency medicine, and all those involved with the management of patients with coronavirus.
Learning Objectives for the Episode 11
- Explains what information all outpatients that have COVID-19 should receive.
- Discusses approved therapies for COVID-19 and who benefit most from these therapies.
- Discusses agents that should not be used for COVID-19.
- Discusses future strategies and agents on the horizon for COVID-19.
Program Registration Information
Registration Fees - $0.00
Continuing Medical Education Education Credit - Accreditation and Designation Statement
UT Health Science Center San Antonio is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
UT Health Science Center San Antonio designates this enduring material for a maximum of .25 AMA PRA Category 1 Creditsâ„¢. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Certificate of Attendance
Healthcare professionals will receive a certificate of attendance and are asked to consult with their licensing board for information on applicability and acceptance.
Credit may be obtained upon successful completion of the activity’s evaluation.
Release date: 08/24/2022 Credits expire: 08/24/2023
-
Faculty
Jan E. Patterson, MD, MS, MACP
FIDSA, FSHEA, CHCP
Professor of Medicine/Infectious Diseases and Pathology
Associate Dean for Quality & Lifelong Learning
Joe R. and Teresa Lozano Long School of Medicine
51²è¹ÝDr. Patterson is a Professor of Medicine/Infectious Diseases and Associate Dean for Quality & Lifelong Learning at The Joe R. and Teresa Lozano Long School of Medicine, 51²è¹Ý. She is clinician and a healthcare epidemiologist and has served on the Infectious Diseases Society of America Board of Directors and is Past President of the Society for Healthcare Epidemiology of America. She is a longtime infectious diseases consultant to Southwest Texas Regional Advisory Council (STRAC) and has also served on CDC’s Healthcare Infection Practices Advisory Committee and has been a consultant to San Antonio Metro Health Department. She has been a site principal investigator for new antimicrobial agents and is currently a co-investigator for the NIH Adaptive COVID-19 Treatment Trial (ACTT) studies as outlined above and is a sub-investigator for the Novavax SARS-CoV-2 vaccine trial at UT Health and University Hospital.
Financial Disclosure: Dr. Jan Patterson has been a site principal investigator for new antimicrobial agents and was a co-investigator for the NIH Adaptive COVID-19 Treatment Trial (ACTT) studies, NIH Accelerating COVID-10 Therapeutic Interventions and Vaccines studies (ACTIV-6) and a sub-investigator for the Novavax SARS-CoV-2 vaccine trial at UT Health and University Hospital.
Jason Bowling, MD
Associate Professor of Medicine/Infectious Diseases
Joe R. and Teresa Lozano Long School of Medicine
51²è¹ÝDr. Bowling is an Associate Professor of Medicine, Division of Infectious Diseases at the Joe R. and Teresa Lozano Long School of Medicine, 51²è¹Ý. He is a clinician and a healthcare epidemiologist at University Health. He is also an investigator for the Adaptive COVID-19 Treatment Trial (ACTT) conducted at University Hospital and a sub-investigator for the Novavax SARS-CoV-2 vaccine trial at UT Health and University Hospital.
Financial Disclosure: Dr. Jason Bowling has disclosed that he is a NIH ACTT co- investigator and sub-investigator for the Novavax SARS-CoV-2 vaccine trial and is a consultant, advisor, and has an executive role with Eli Lilly.
